ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Integrative Omics Defines Metabolic Biomarkers and Genetic Regulatory Mechanisms of Mortality Risk.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Effects of anVeterinary sciences · 2026Article
- Beyond metabolism and blood flow: toward an inflammation-metabolism axis paradigm for herbal medicine in obesity-related coronary heart disease.Frontiers in cardiovascular medicine · 2026Article
- Deciphering host-virus interaction networks in ALV infection: an integrative multi-omics perspective.Frontiers in immunology · 2026Review
- Integrative Omics Defines Metabolic Biomarkers and Genetic Regulatory Mechanisms of Mortality Risk.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The genetic and metabolic architecture of mortality risk represents a fundamental, yet poorly understood, challenge in human medicine and livestock breeding. Here serum metabolomics and multi-omics data is integrated in a designed 3-generation chicken model (n = 1,277) with divergent mortality. The analysis reveals a trade-off between heightened inflammatory responses and impaired growth in susceptible animals. To uncover the genetic underpinnings, 45,585 metabolite quantitative trait loci are identified, which are predominantly enriched among liver-specific regulatory variants. Using a machine learning approach, a robust 16-metabolite signature is established, including hexyl glucoside and pyrraline, that accurately predicts mortality risk. Importantly, these metabolites and their genetic loci offer practical targets for genomic selection in chicken breeding, providing a direct approach to enhance disease resistance and survival. Cross-species comparison with human data revealed conserved metabolic dysregulation pathways, while also highlighting species-specific immuno-metabolic pathophysiology. Furthermore, the findings pinpoint butyrate-mediated microbiota-host interactions and the dual antioxidant functions of L-cysteine as critical regulatory mechanisms. Together, these results delineate an evolutionarily conserved immuno-metabolic framework for mortality risk, offering novel biomarkers for selective breeding and potential therapeutic targets for human metabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.